Ovid Therapeutics (OVID) Price & Analysis

Compare

1,713 Followers

OVID Stock Chart & Stats

$1.55

-$0.03(-2.93%)

At close: Jan 08 4:00 PM EST

$1.55

-$0.03(-2.93%)

Day’s Range― - ―

52-Week Range$0.24 - $2.01

Previous CloseN/A

Volume22.63K

Average Volume (3M)1.39M

Market Cap

$235.63M

Enterprise Value$103.53M

Total Cash (Recent Filing)$25.60M

Total Debt (Recent Filing)$13.76M

Price to Earnings (P/E)―

Beta2.36

Next Earnings

Mar 16, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding130,184,360

10 Day Avg. Volume1,228,345

30 Day Avg. Volume1,390,657

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)0.97

Price to Sales (P/S)116.97

P/FCF Ratio-1.18

Enterprise Value/Market Cap0.44

Enterprise Value/Revenue15.66

Enterprise Value/Gross Profit15.70

Enterprise Value/Ebitda-2.57

Forecast

1Y Price Target

$4.17

Price Target Upside169.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Data For OV329Phase 1 biomarker and safety results for OV329 show on-target GABA activity with no ophthalmic safety findings, supporting advancement into a placebo-controlled Phase 2a study.

Financing And RunwayRecent financing and warrant-related proceeds extend cash runway into 2028, providing funding to execute planned Phase 2 trials for lead programs.

KCC2 Program ValidationPhase 1 results for the KCC2 activator OV350 demonstrated a clean safety profile and EEG biomarker changes consistent with target engagement, validating a novel mechanism for seizure control.

Bears Say

Historical Execution RiskA track record that includes multiple late-stage program failures highlights execution risk and may reduce confidence in achieving successful late-stage outcomes.

Safety And Regulatory RiskPersistent concern about potential retinal or ophthalmic toxicity with GABA-AT inhibitors like OV329 represents a material safety and regulatory risk that could limit approval or clinician uptake.

Tolerability ConcernsHeadache reported as the most frequent treatment-emergent adverse event with OV350 could create tolerability issues that complicate dosing strategies or patient retention in trials.

Ovid Therapeutics News

CWAN, HTBK, OVID, MCFT, WHWK Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CWAN) ), ( ($HTBK) ), ( ($OVID) ), ( ($MCFT)...

1M ago

CWAN

HTBK

Ovid Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $4 price target Published first...

1M ago

OVID

Ovid Therapeutics: Positive KCC2 Platform Progress and Underappreciated Pipeline Optionality Support Reiterated Buy Rating

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on OVID stock, giving a Buy rating on...

1M ago

OVID

Ovid Therapeutics: De-Risked KCC2 Platform and OV329 as Key Drivers of Long-Term Growth Support Buy Rating

Analyst Thomas Shrader of BTIG maintained a Buy rating on Ovid Therapeutics, retaining the price target of $4.00....

1M ago

OVID

Ovid Therapeutics: Early KCC2 Proof-of-Mechanism and High-Potency OV4071 Pipeline Support Buy Rating and Attractive Long-Term Risk‑Reward

William Blair analyst Myles Minter has maintained their bullish stance on OVID stock, giving a Buy rating on...

1M ago

OVID

Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data

The latest announcement is out from Ovid Therapeutics ( ($OVID) ). On December 18, 2025, Ovid Therapeutics reported...

1M ago

OVID

Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV

Ovid Therapeutics (OVID) announced results from its Phase 1 study of OV350, the first-ever Potassium-Chloride Cotransporter 2, KCC2,...

1M ago

OVID

Ovid Therapeutics files to sell 125.06M shares of common stock for holders

17:27 EST Ovid Therapeutics (OVID) files to sell 125.06M shares of common stock for holders Published first on...

2M ago

OVID

Ovid Therapeutics Stockholders Approve Key Proposals

Ovid Therapeutics ( ($OVID) ) has issued an announcement. On December 11, 2025, Ovid Therapeutics held a special...

2M ago

OVID

Ovid Therapeutics initiated with a Buy at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $3 price...

2M ago

OVID

Ovid Therapeutics appoints Kaufmann as Chief Medical Officer

Ovid Therapeutics (OVID) announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann...

2M ago

OVID

Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ovid Therapeutics (OVID) to $2 from $1.50 and keeps a...

2M ago

OVID

Leerink bullish on Ovid Therapeutics, initiates with an Outperform

As previously reported, Leerink analyst Marc Goodman initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and...

2M ago

OVID

Ovid Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $5 price target Published first on...

2M ago

OVID

OVID FAQ

What was Ovid Therapeutics Inc’s price range in the past 12 months?

Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $2.01 in the past 12 months.

What is Ovid Therapeutics Inc’s market cap?

Ovid Therapeutics Inc’s market cap is $235.63M.

When is Ovid Therapeutics Inc’s upcoming earnings report date?

Ovid Therapeutics Inc’s upcoming earnings report date is Mar 16, 2026 which is in 45 days.

How were Ovid Therapeutics Inc’s earnings last quarter?

Ovid Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.02.

Is Ovid Therapeutics Inc overvalued?

According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ovid Therapeutics Inc pay dividends?

Ovid Therapeutics Inc does not currently pay dividends.

What is Ovid Therapeutics Inc’s EPS estimate?

Ovid Therapeutics Inc’s EPS estimate is -0.12.

How many shares outstanding does Ovid Therapeutics Inc have?

Ovid Therapeutics Inc has 130,184,360 shares outstanding.

What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?

Ovid Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -2.222%.

Which hedge fund is a major shareholder of Ovid Therapeutics Inc?

Currently, no hedge funds are holding shares in OVID

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ovid Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-60.06%

Trailing 12-Months

Asset Growth

-37.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics (OVID) Earnings & Revenues

Historic Earnings Reports

OVID Stock 12 Month Forecast

Average Price Target

$4.17

▲(169.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.63,2.043076923076923,2.456153846153846,2.869230769230769,3.2823076923076924,3.695384615384615,4.108461538461539,4.521538461538461,4.934615384615384,5.3476923076923075,5.76076923076923,6.173846153846154,6.586923076923076,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.63,1.8253846153846154,2.020769230769231,2.216153846153846,2.4115384615384614,2.606923076923077,2.802307692307692,2.9976923076923074,3.193076923076923,3.3884615384615384,3.583846153846154,3.779230769230769,3.9746153846153844,{"y":4.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.63,1.6584615384615384,1.6869230769230767,1.7153846153846153,1.7438461538461538,1.7723076923076921,1.8007692307692307,1.8292307692307692,1.8576923076923078,1.886153846153846,1.9146153846153846,1.943076923076923,1.9715384615384615,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.933,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.663,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.309,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.315,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.289,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.316,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >